Výsledky vyhledávání - "E Mateos Egido"

5PSQ-065 Inmunotherapy: recognising and treating adverse effects

Autor: I Ruiz Santos, E Mateos Egido, A Dominguez Fariña, G Avanzini Martinez, F Madriñán Gonzalez, M Lombardero Pin

Publikováno v: Section 5: Patient safety and quality assurance.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::98a1a653d3d67470bb6da5913f25b93c
https://doi.org/10.1136/ejhpharm-2022-eahp.293

Zobrazit plný text záznamu

1ISG-007 Economic savings from weight-based dosing of pembrolizumab: what is the impact in a tertiary hospital?

Autor: E Mateos Egido, A Dominguez Fariña, ÁMAttenya María, D Dorta Vera, I Ruiz Santos, M Lombardero Pin, C Otero Villalustre, ME Luján López, D Fernández Vera

Publikováno v: Section 1: Introductory statements and governance.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c956687475eda36aeb3e2f9d9e56ac6a
https://doi.org/10.1136/ejhpharm-2022-eahp.5

Zobrazit plný text záznamu

1ISG-006 Estimation of drug cost avoidance in clinical trials of non-small cell lung cancer

Autor: E Mateos Egido, AM Álamo Medina, A Dominguez Fariña, I Ruíz Santos, ME Luján López, M Lombardero Pin, C Otero Villalustre, D Fernández Vera

Publikováno v: Section 1: Introductory statements and governance.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e05880e69f6c48dd91335923279215ce
https://doi.org/10.1136/ejhpharm-2022-eahp.4

Zobrazit plný text záznamu

4CPS-118 Experience of dual targeting use of neoadjuvant HER2-positive breast cancer

Autor: E Mateos Egido, D Fernandez Vera, A Alamo Medina, M Lombardero Pin, ME Luján López

Publikováno v: Section 4: Clinical Pharmacy Services.

Background Neoadjuvant chemotherapy is the treatment of choice in locally advanced breast carcinoma. Pertuzumab is approved in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2 positive breast cancer. P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1f724560178bc97ba908f41de72b76f
https://doi.org/10.1136/ejhpharm-2019-eahpconf.267

Zobrazit plný text záznamu

5PSQ-054 Drugs that extend the qt interval of the ecg: evaluation of oncological patients

Autor: A Alamo Medina, M Lombardero Pin, E Mateos Egido, ME Luján López, LSantos Morín

Publikováno v: Eur J Hosp Pharm

Background Detection of drugs that produce prolongation of the QT interval is very important. Purpose Oncological patients have an associated risk for QT prolongation due to hydroelectrolyte disturbances associated with their pathologies and the trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4811fe177f0fd42cbbc25a7914f8a726
https://doi.org/10.1136/ejhpharm-2018-eahpconf.408

Zobrazit plný text záznamu